- Home
- ELEV vs FGEN Comparison
ELEV vs FGEN Comparison
Compare ELEV & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- FGEN
- Stock Information
- Founded
- ELEV 2019
- FGEN 1993
- Country
- ELEV United States
- FGEN United States
- Employees
- ELEV N/A
- FGEN N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- FGEN Health Care
- Exchange
- ELEV Nasdaq
- FGEN Nasdaq
- Market Cap
- ELEV 37.6M
- FGEN 34.5M
- IPO Year
- ELEV 2021
- FGEN 2014
- Fundamental
- Price
- ELEV $0.58
- FGEN $0.40
- Analyst Decision
- ELEV Strong Buy
- FGEN
- Analyst Count
- ELEV 5
- FGEN 0
- Target Price
- ELEV $7.20
- FGEN N/A
- AVG Volume (30 Days)
- ELEV 860.8K
- FGEN 996.1K
- Earning Date
- ELEV 11-06-2024
- FGEN 11-12-2024
- Dividend Yield
- ELEV N/A
- FGEN N/A
- EPS Growth
- ELEV N/A
- FGEN N/A
- EPS
- ELEV N/A
- FGEN N/A
- Revenue
- ELEV N/A
- FGEN $180,015,000.00
- Revenue This Year
- ELEV N/A
- FGEN $19.67
- Revenue Next Year
- ELEV N/A
- FGEN N/A
- P/E Ratio
- ELEV N/A
- FGEN N/A
- Revenue Growth
- ELEV N/A
- FGEN 16.15
- 52 Week Low
- ELEV $0.44
- FGEN $0.18
- 52 Week High
- ELEV $5.83
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- ELEV 43.94
- FGEN 58.65
- Support Level
- ELEV $0.60
- FGEN $0.34
- Resistance Level
- ELEV $0.70
- FGEN $0.37
- Average True Range (ATR)
- ELEV 0.08
- FGEN 0.04
- MACD
- ELEV -0.01
- FGEN -0.00
- Stochastic Oscillator
- ELEV 7.67
- FGEN 76.07
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.